Roberts, Thomas M.

CDK4/6 inhibition triggers anti-tumour immunity

Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature

Cancer Immunotherapy and BiomarkersAdvanced Breast Cancer Therapies

Cited by 1,513

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 1,460

Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations

Pugh, T. J., Weeraratne, S. D., Archer, T. C., Pomeranz Krummel, D. A., Auclair, D., Bochicchio, J., Carneiro, M. O., Carter, S. L., Cibulskis, K., Erlich, R. L., et al. (2012) · Nature

Glioma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 750

KRAS and YAP1 Converge to Regulate EMT and Tumor Survival

Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell

Hippo pathway signaling and YAP/TAZProtein Kinase Regulation and GTPase Signaling

Cited by 744

PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer

Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports

PARP inhibition in cancer therapyCancer Immunotherapy and Biomarkers

Cited by 572

The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival

Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., et al. (2017) · Nature

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 347

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer

Wang, D., Wang, M., Jiang, N., Zhang, Y., Bian, X., Wang, X., Roberts, T. M., Zhao, J. J., Liu, P., & Cheng, H. (2016) · Oncotarget

PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment

Cited by 88

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer

Nam, G.-H., Kwon, M., Jung, H., Ko, E., Kim, S. A., Choi, Y., Song, S. J., Kim, S., Lee, Y., Kim, G. B., et al. (2021) · Journal for ImmunoTherapy of Cancer

Cancer, Lipids, and MetabolismCancer Immunotherapy and Biomarkers

Cited by 82

A Non-Canonical Function of Zebrafish Telomerase Reverse Transcriptase Is Required for Developmental Hematopoiesis

Imamura, S., Uchiyama, J., Koshimizu, E., Hanai, J.-I., Raftopoulou, C., Murphey, R. D., Bayliss, P. E., Imai, Y., Burns, C. E., Masutomi, K., et al. (2008) · PLoS ONE

Telomeres, Telomerase, and SenescenceZebrafish Biomedical Research Applications

Cited by 58

PI3K alpha and delta promote hematopoietic stem cell activation

Hemmati, S., Sinclair, T., Tong, M., Bartholdy, B., Okabe, R. O., Ames, K., Ostrodka, L., Haque, T., Kaur, I., Mills, T. S., et al. (2019) · JCI Insight

Hematopoietic Stem Cell TransplantationPI3K/AKT/mTOR signaling in cancer

Cited by 40